This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that its Chairman and CEO, Robert Stockman, is presenting at the 31
st Annual J.P. Morgan Healthcare Conference at 1:30 p.m. US PST on Thursday, January 10, 2013. The conference is being held January 7 through 10, 2013 at The Westin St. Francis Hotel in San Francisco, California.
A copy of the presentation materials will be available on REVA's website at
www.revamedical.com shortly before the presentation.
REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary bioresorbable stent products. REVA's initial product, the
ReZolve® scaffold, which is in a clinical study phase, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. The
ReZolve scaffold is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the
ReZolve scaffold may reduce the incidence of late forming blood clots or otherwise reduce long-term disease progression, potential benefits of bioresorbable scaffolds that have yet to be proven. REVA will require clinical results and regulatory approval before it can begin selling the
The REVA Medical, Inc. logo is available at
CONTACT: United States
Investor and Media Enquiries:
Director, Investor Relations and Marketing
REVA Medical, Inc.
+1 858 966-3045
Kim Jacobs or Alan Taylor
+61 2 9231 3322
Haley Price or Rebecca Wilson
+61 3 9866 4722